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ABSTRACT
A number of monoclonal antibodies have been raised against CD4, the receptor on T cells for the HIV enve-
lope glycoprotein gp 120. In the present paper we describe biological activities and sequence analysis of seven
CD4 MAb. Five of these MAb preparations compete with HIV/gpl20 for CD4 binding. The sequences of the
variable regions for these MAb were determined in order to ascertain any correlation with selective V gene
usage. A relationship was found between the expressed variable region genes and the CD4 recognition pat-
tern. The VH genes that are used can be subdivided into two major groups expressing either a Vh gene be-
longing to the J558 family or to the VGam family. The usage of the VL genes varies, indicating that the epi-
tope specificity is predominantly determined by the rearranged VH genes. The distinct cross-reactivity pattern
of these MAb also correlates with their capacity to block binding of recombinant gpl20 to CD4 in vitro.
Although five of these MAb were able to block gpl20 binding none of the CDR sequences shows a relevant
homology to the gpl20 sequence. This indicates a steric hinderence mechanism for blocking gpl20 binding
and not a direct interaction with the receptor binding site on CD4. The data also confirm the failure of these
MAb as a potential target for receptor mimicry.
INTRODUCTION
THE UNIQUE FEATURE OF IMMUNOGLOBULINS ÍS the enOITTlOUSdiversity of their variable region segments and their abil-
ity to interact with an unlimited number of determinants. The
immunoglobulin (Ig) variable (V) regions are encoded by mul-
tiple DNA segments that rearrange during B cell differentia-
tion'1' to form a complete variable region gene. Each heavy and
light chain variable region is subdivided into four framework
regions separated by three complementarity determining re-
gions (CDR). The Ig V regions can be divided into families ac-
cording to protein and nucleic acid similarities. In the murine
systems there are a minimum of 11 VH and 29 Vk gene fami-
lies/2"6' The structural basis of antibody complementarity and
the origin of sequence diversification in V region genes have
been studied in several systems/7-13' The results of these stud-
ies allowed a correlation of V region sequences with antigen-
binding specificity.
The present paper reports V region sequences of seven CD4
MAb. The CD4 glycoprotein is predominantly found on the
helper subset of T lymphocytes'1415' and of cells of the mono-
cyte-macrophage lineage/16-17' In addition to its physiological
function as a regulator of the immune system"8' CD4 serves
also as a target for HIV attachment mediated by the viral en-
velope glycoprotein gpl20."9-20) The interaction has been
mapped to the first Ig-like domain of CD4/21_23) MAb directed
to this region are potent inhibitors of HIV-replication and also
of HIV-«iv-induced syncytium formation. It has been suggested
that variable region determinants could imitate determinants on
unrelated molecules/24-25' The analyzed CD4-specific MAb
were raised to identify MAbs that were able to block the CD4-
HIV/gpl20 interaction and thus allow the generation of poten-
tial anti-idiotype receptor antibodies.
The reported V region sequences of seven CD4 MAb can be
subdivided into two groups represented by M-T310 and M-
T151. The heavy chains with closely related frameworks are
combined with different Vk light chain genes of four Vk sub-
groups indicating that the epitope specificity is primarily de-
termined by the VH region gene. Five of the analyzed CD4 MAb
recognize epitopes that overlap the HIV/gpl20 binding site.
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Three of the analyzed MAb seem to be closely related as they
bind to the same or an overlapping epitope on the CD4 mole-
cule. Mapping of the CD4 binding site for human immunode-
ficiency virus by mutagenesis identified amino acid residues
that affect both the gpl20-binding pattern and the reactivity of
MAb M-T310 and M-T151/26-28' The three-dimensional struc-
ture of the first and second domain of the CD4 molecule'29-30'
shows that the residues involved in M-T310 and M-T151 bind-
ing are stereoscopically separated, indicating the residues out-
side of the CDR2-like region of the CD4 molecule are also in-
volved in the gpl20/CD4 interaction. The role of CD4-D1
CDR3-like loop in syncytium formation is controversial/31-33'
MATERIALS AND METHODS
Cell lines and mAbs
The hybridomas M-T310, M-T404, M-T413, M-T408, M-
T321, M-T151, and M-T406 secreting CD4 MAb were obtained
by fusion of BALB/c immune spleen cells to the nonsecreting
myeloma line (X63) P3X63-Ag8.653 (American Type Culture
Collection CRL 1580). Cells were grown in normal RPMI
medium for DNA and RNA isolation and for amplification of
hybridoma proteins in serum-free medium. Antibody purifica-
tion was performed as described/34'
Inhibition of HIV-1 rgpl20 binding
Inhibition of HIV-1 gpl20 binding by CD4 MAb was de-
termined by an immunofluorescence assay: peripheral blood
lymphocytes (PBL) (2 X 105) were preincubated with 3-fold
dilutions of CD4 MAb starting from 30 pg/ml for 30 min on
ice. The supernatant was removed and cells were incubated with
recombinant gpl20 (rgpl20) for a further 20 min on ice. As a
source for rgp 120 we used concentrated culture supernatant of
gpl20 secreting CHO transfectoma cell line ADP 240/17.1
made available by H.C. Holmes, MRC AIDS Reagent Project,
London, GB. Bound rgpl20 was detected with the specific bi-
otinylated anti-gpl20 MAb 108, provided by D. Healey, MRC,
London, UK, and fluorescein-conjugated streptavidin (Dianova,
Hamburg, FRG). After fixing with 1 % paraformaldehyde fluo-
rescence intensity was quantified by FACScan analysis as flu-
orescence mean channel of living cells on log scale.
Binding competition of CD4 mAb
PBL were preincubated with purified CD4 MAb at 40 pg/ml
for 60 min on ice. Cells were spun down and stained with a
second biotinylated CD4 MAb for 30 min on ice, followed by
a third incubation with fluorescein-conjugated avidin.
Concentration of biotinylated MAb was selected to give thres-
hold saturating staining without inhibitor. Staining intensity was
measured by flow cytometry and the reduction of fluorescence
mean channels was calculated compared to samples preincu-
bated with unrelated CD MAb.
Relative binding affinity of CD4 mAb
Binding affinity of MAb M-T151 has been determined by
Scatchard Plot. The relative binding affinities of all other ana-
lyzed MAb have been determined relative to MAb M-Tl 51 with
a value set at 1.0. Briefly 105 thymocytes were incubated with
serially diluted MAb in 50 pi tissue culture medium in mi-
crotiter wells for 20 min on ice. Cells were washed twice with
ice cold PBS and stained with fluorescein-conjugated F(ab')2
rabbit antimouse Ig.
Fluorescence mean channel determined by flow cytometry
was plotted versus log CD4 MAb concentration resulting in sig-
moid titration curves. The relative binding affinity was calcu-
lated from the distance between titration curves for MAb M-
T151 and respective antibodies.
Syncytium inhibition assay
The test was set up 10 times in flat-bottom microtiter plates;
0.5 X 105 C8166 cells were incubated with serial dilution of
CD4 MAb beginning with a concentration of 40 pg/ml in 100
pi RPMI medium for 60 min, then 1000 TCID50 of HIV-1 strain
MVP-899 was added for a culture period of 6 days. Formation
of giant cells (syncytia) was visually controlled under an in-
verted microscope. As inhibition titer the lowest MAb concen-
tration was given at which not more than one syncytium was
detectable per well.
Sequence analysis of immunoglobulin mRNA
Total RNA was prepared using standard methods/35' The
RNA yield of 4 X 107 cells (300 to 400 pg total RNA) was
subjected to cDNA synthesis. The following synthetic oligonu-
cleotide primers, which hybridize to immunoglobulin mRNA
3' of the V-C junction, were synthesized by the phospho-
ramidite method with an Applied Biosystems Synthesizer and
purified by polyacrylamide gel electrophoresis. The heavy chain
oligonucleotide 5'-GGGGCCAGTGGATAGAC-3' cross-hy-
bridized with yl, y2a, and y2b transcripts 21 bases 3' from the
V-C junction, whereas the light chain oligonucleotide 5'-
AGATGGATACAGTTGGT-3' cross-hybridized with k tran-
scripts 38 bases 3' of the Vk region. CDNA synthesis was per-
formed with 32P-labeled oligonucleotides simultaneously on
heavy and light chain mRNA as described/7' Full length cDNA
copies of the V regions were fractionated on polyacrylamide
gels, eluted from gel slices, and then sequenced according to
the method of Maxam and Gilbert/36'
RESULTS
Binding specificity of CD4 mAb
Seven hybridomas secreting anti-CD4 MAb were obtained
from six different fusions after immunization of different
BALB/c mice with either cells from chronic lymphocytic
leukemias of T type or transfectants of mouse P815 mastocy-
toma cells expressing human CD4. Only two MAb, M-T151
and M-T321, are derived from the same fusion. All MAb ex-
press a k light chain, five MAb use a yl, and two mAb a y2a
isotype for their heavy chain (Table 1). The binding competi-
tion analysis of seven CD4 MAb (Fig. 1) indicates an overall
distribution into two roughly distinct groups. The assay shows
further that MAb of the M-T310 group block each other more
effectively than the members of the other group. This implies
that M-T310, M-T404, and M-T413 recognize the same or an
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Table 1. Relative CD4 MAb Affinity and Interference
with Virus (HIV) Binding
Relative Total Inhibition
binding inhibition of HIV-1
affinity ofrgpl20 MVP-899
= 109 M~' " bindingh infection1CD4 MAb Isotype K
M-T310
M-T404
M-T413
M-T408
M-T151
M-T321
M-T406
yl//c
yllK
yl/K
yl/K
y2a/K
yl/K
y2alK
8.2
6.1
8.6
0.3
1.0
0.6
0.9
0.3
0.3
0.1
10.0
10.0
0.03-0.1
1.0-3.0
0.03
3.0
aThe binding affinity of CD4 MAb relative to MAb M-T151.
bMAb concentration (pg/ml) at which binding of HIV rgp 120
is totally reduced on the basis of log scale fluorescence inten-
sity.
The minimum MAb concentration (pg/ml) required to com-
pletely block infection and syncytium formation in 1 X 105
C8166 cells after challenge with 1000 TCID50 of HIV-1 MVP-
899 strain (—, no inhibition at 20 pg/ml).
overlapping epitope on the CD4 molecule. M-T408 may have
contacts to both antigenic regions recognized by the two groups,
as this MAb blocks all analyzed MAb except M-T321 and M-
T151. The binding competition of the M-T151 group members
is not as stringent as for M-T310 group members, which might
be in part explained by their large differences in affinity. But
they could also recognize different epitopes or only structurally
overlapping or neighboring epitopes.
The relative binding affinity of MAb and their interference
with HIV-1 binding is shown in Table 1. The inhibition of rgp
120 binding and HIV-1 infection in vitro correlates with the
CD4 binding pattern. Only M-T310, M-T404, and M-T413 with
an identical cross-blocking pattern also interfere effectively in
low concentrations with rgp 120 binding and HIV-1 infection
mAb
M-T310
M-T404
M-T413
YÜ
J558
J558
J558
O ^ (O CO H ri W
„
r-ioi-tomcMoVK w ^ ^ <t H ffl S1
21
M-T408 VGam
M-T151 VGam
M-T321 VGam
M-T406 VGam
21
21
23
10
21
FIG. 1. Binding competition analysis of CD4 MAb is shown
as the reduction of fluorescence mean channel, measured by
flow cytometry. The reduction of fluorescence mean channel is
indicated as follows: open squares: <59; gray stippled squares:
60-119; dark stippled squares: 120-179; black squares: >180.
The Vh and Vk: gene families from which the V regions were
derived are indicated. The hybridomas have been placed into
sets that use the same or similar V genes, and that display sim-
ilar reactivity patterns.
in vitro. In the second group according to the VH gene usage
only MAb M-T151 and M-T408 show total inhibition of rgpl20
binding in a 3- to 10-fold higher concentration than members
of the M-T310 group. The relative CD4 binding affinity of
members of the M-T151 group is also reduced by a factor 3 to
10 in comparison to MAb of M-T310 group. Moreover only
MAb M-T151 inhibits HIV-1 infection in vitro. These assays
on interference with HIV-1 binding show that five of the MAb
recognize epitopes that interfere with the HIV binding site on
the CD4 molecule.
Heavy chain analysis
Sequence analysis of the CD4 MAb showed that productive
VH region genes can be attributed to two different VH gene fam-
ilies. The gene families comprise groups of related V genes that
in general share greater than 80% sequence similarity. The VH
region genes of MAb M-T310, M-T404, and M-T413 are mem-
bers of the largest V gene family J558 and the VH region genes
of mAb M-T151, M-T321, M-T406, and M-T408 are members
of the VGam gene family (Fig. 2). The few sequence differ-
ences of M-T310, M-T404, and M-T413 VH region genes in-
dicate that they are very closely related members of a gene fam-
ily. They share at least 92.9% homology among themselves.
The VH region sequences of the second group are all very
closely related to the VGam VH gene and share at least 88.2%
homology among themselves.
In contrast to the sequence similarity displayed by the VH
regions, the D regions used in the hybridomas of related speci-
ficity exhibit a marked diversity both in sequence and length.
The diverse nature of these sequences does not allow a precise
determination of VH-D and D-JH boundaries. Although none of
these somatic D regions corresponds exactly to identified
germline D segments'37' they all show regions of homology
flanked by relatively G-rich sequences (N sequences) that pre-
viously have been proposed to be inserted during VH-D and D-
JH joining events/38' The overall length of the D regions varies
from 24 to 36 nucleotides, showing preferential homology to
members of DSP2 and DFL 16 D region gene segments (Fig.
2). The analyzed VH members of the M-T310 group show a D-
J3 rearrangement, while the VH gene members of the M-T151
group have conveyed their D rearrangements to J2, J3, and J4.
In addition, no sequence homology in the CDR of either heavy
or light chain to the gpl20 sequence has been found.
Light chain analysis
The nucleotide and deduced amino acid sequences of seven
different CD4-specific L chain variable regions are shown in
Figure 3. The V region sequences can be subdivided into four
different subgroups according to their homology (>80%) to the
16 or 18 different Vk gene families/4-6' The MAb M-T310, M-
T404, M-T413, and M-T321 use V region genes homologous
to members of the subgroup 21. The high sequence homology
of 89.3 to 100% among these VL regions indicates that these V
genes are closely related. The differences in sequence could be
explained by somatic mutation. MAb M-T408 uses a VL region
homologous to members of the Vk subgroup/23' MAb M-T406
has a VL region gene member of the subgroup 8 and MAb M-
T151 a member of the subgroup 10 rearranged. All Vk regions
used by the analyzed MAb rearranged to either Jl or J2.
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FIG. 2. Nucleotide sequence and deduced amino acid sequence alignment of the VH regions of seven MAb to CD4. Sequences
are grouped according to the indicated VH gene families, and are displayed relative to a representative from each group. The de-
duced amino acid sequences are numbered according to Kabat et a/.,'4' and the locations of CDR are shown. The symbol (—)
corresponds to the same amino acid or nucleotide and the symbol (•) represents a gap in comparison to the representative se-
quence. The used J and D sequence elements are indicated at the end. Nucleotides homologous to known D segments are shown
in small letters. These nucleotide sequences and those shown in Figure 3 have been submitted to the EMBL GenBank and DDBJ
Nucleotide Sequence Databases and assigned accession numbes X65084-X65097. Sequences encoding VH and Vk regions of
MAb M-T310 and M-T151 have been published/57'
DISCUSSION
The sequence of the heavy and light chain variable regions
of seven CD4 MAb was determined to ascertain whether struc-
tural features are shared by antibodies that recognize CD4 and
interfere with gpl20/CD4 recognition. This analysis revealed
homology between VH gene segments, and allowed their dis-
tribution into two groups. Members of the two families show a
similar reactivity pattern, indicating that they recognize the
same or a structurally overlapping epitope.
The correlation of V usage with binding specificity has been
described for other antigens including influenza virus hemag-
glutinin/7' digoxin/10' cyclosporin A/12' and the antibody re-
sponse to the Haemophilus influenzae type B capsular poly-
saccharide/13) Extensive examinations of the antibody response
to antigenic regions on the influenza hemagglutinin'39' and the
analysis of a large panel of MAb specific for a(l-6)dextran'40'
revealed that there is no apparent constraint for the utilization
of specific gene families. This implies that V region genes of
nearly every family can contribute to the V domain pool of an
antibody response to a certain antigenic region.
Lohman et a//41' described biological activities and struc-
tural features of seven CD4 MAb. The authors show that five
of these MAb block CD4/gpl20 interaction and also syncytia
formation efficiently. In this context it is remarkable that the
sequence analysis reveals that the V region k chain from each
of the seven MAb is encoded by the Vk21 gene family. Six of
the MAb use a VH gene region encoded by the J558 gene fam-
ily and one MAb uses a member of the VGam gene family. In
addition to the high sequence homology in the V gene regions,
MAb M-T310 and MAb Leu3a also show a high degree of
amino acid sequence homology in the VH CDR3 region en-
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coded by D minigenes. According to the biological activities
and the shared structural features we conclude that at least MAb
M-T310, M-T413, and M-T404, which all block binding of
Leu3a to CD4 in a cross-blocking experiment (data not shown),
recognize the same or an overlapping epitope on the CD4 mol-
ecule. Although by analyzing a larger panel of hybridomas se-
creting CD4 MAb with rgp 120 cross-blocking capacity one
might find usage of more different V gene families, it indicates
a structural and functional restricted antibody response to this
defined antigenic region on the CD4 molecule.
The distinct specificity of the analyzed MAb is influenced
by VH CDR3, which differs in sequence and in length, leading
to perhaps different contacts to the CD4 molecule. The closely
related binding specificity of the M-T310 group members may
also be supported by the usage of homologous VL gene seg-
ments. The usage of VL gene segments in the M-T151 group
is more heterogeneous. In this case not only CDR3 but also the
light chain V region might contribute to differences in fine
specificity. Studies on MAb specific for hemagglutinin'7-39' and
lysozyme'42' revealed that VH gene segments combined with
different VL gene segments can have the same epitope speci-
ficity. It has been suggested that the combination of VH with
any VL that allows formation of the combining site without cre-
ating unfavorable steric or electrostatic interactions should pre-
serve a significant portion of antibody specificity/43' Thus, the
antigen-binding specificity directed by VH is preserved. This
view is further supported by the result of Kabat and Wu,'44'
who examined a large database of amino acid sequences of an-
tibodies with various specificities. They found many antibod-
ies of distinctly different specificities assemble identical VL do-
mains with different VH domains. Moreover, this may hold true
for the members of the M-T151 group, which all use VL gene
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FIG. 3. Nucleotide sequence and deduced amino acid sequence alignment of the Vk regions of seven MAb to CD4. Sequences
are grouped according to the indicated Vk gene families, and are displayed relative to a representative from each group. The de-
duced amino acid sequences are numbered according to Kabat et a/./4' and the locations of CDR are shown. The symbol (—)
corresponds to the same amino acid or nucleotide and the symbol (•) represents a gap in comparison to the representative se-
quence. The used J sequence elements are indicated at the end.
122 WEISSENHORN ET AL.
segments homologous to different Vk subgroups. This may also
hold true for the usages of a very similar VL domain by M-
T321 and the members of the M-T310 VH gene family.
The CD4 binding specificities of MAb M-T310, M-T321, and
M-T151 have been characterized by several groups. CD4 specific
amino acids 42 and 43 are involved in binding of MAb M-T310,
whereas for MAb M-T321 positions 17, 24, 25, 88, and 89 and for
MAb M-T151 amino acids 1, 72, 94, 95, and 165 are critical for
antibody-antigen interaction/26-28' By the same approach the
gpl20 binding site was mapped to the N-terminal domain 1 (Dl)
of CD4. Mutation of 19 amino acids in CD4-D1 seem to have an
impact on gpl20 binding without apparent global conformational
changes/26-28-45-46' Thirteen of these residues are in the CDR2-like
segment (aa 38 to 59). Four locations outside this sequence (aa 29,
59-64, 77-81, and 85) were also identified as potential contact
sites/47' These studies suggest that residues recognized by M-T310
and probably also by M-T404 and M-T413 are shared with the
gpl20 binding site. MAb M-T151 and M-T408 of the second group
do not show the same stringent inhibition of rgp 120 binding, and
only M-T151 can inhibit viral infection in vitro. This may be due
to the lower affinity relative to the other MAb analyzed and thus
allows a displacement by viral gpl20. The gpl20 binding constant
for CD4 has been found to be 4 X 10-9 M for the HIV-IIIB iso-
late/48' Another explanation would be that these MAb do not in-
teract directly with residues of the CD4 molecule identified to in-
teract with gpl20. They might recognize epitope(s) within this
region and thus lead to sterical inhibition of CD4/gpl20 interac-
tion, which again might depend on their affinity.
As a third possibility the binding of CD4 MAb could induce
conformational changes in a distant region of the CD4 mole-
cule, thus influencing the gpl20 interaction. Truneh et a//49'
suggested that the CDR2 and CDR3-like region of CD4-D1
might be sequentially engaged in the binding of different in-
teraction sites on the gpl20 glycoprotein. This study supports
this view that not only the CDR2-like region of CD4-D1 is in-
volved in CD4/gpl20 interaction. The epitope(s) recognized by
MAb of the M-T310 group do not interfere with the M-T151
epitope, but both block binding of rgp 120 and inhibit infection
of HIV-1 in vitro. Conformational changes induced by these
MAb can be excluded as thymocytes can be stained by MAb
M-T310 together with MAb M-T151 in a double fluorescence
(data not shown).
The CDR2-like loop in CD4-D1 as the major binding site for
gpl20 may interact with a compact, highly conserved binding
pocket in gpl20. Theoretically, an anti-idiotypic CD4 MAb,
whose epitope closely resembles the CD4 binding site of gpl20,
may be a better immunogen than gpl20 itself and may elicit an-
tibodies that would outcompete the high affinity virus-receptor
interaction. However, immunization of mice with MAb M-T310
elicited an anti-idiotype response that does not interfere with
CD4/gpl20 interaction/50' Also anti-idiotypes specific for MAb
Leu3a only weakly neutralized HIV/5" An analysis of a panel
of 225 CD4 MAb showed only for one MAb fine specificity that
was broadly like that of gpl20/52) In contrast to these studies
others described anti-idiotypic antibodies raised against CD4
MAb, which showed gpl20-specific activity/53-54'
It has been shown that antireceptor antibodies might share
sequence homologies in their CDR to the ligand/55-56' This is
not the case for either our analysed CD4 MAb or the ones de-
scribed by Lohman et a//41' The data also confirm the failure
of these MAb for being a potential target for the concept of
mimicry between antibodies and receptors.
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